The present invention provides methods for identifying patients at increased risk of developing an adverse neurological event in response to a cancer treatment. Methods also include modifying the treatment regimen of said patent dependent on the presence or absence of biomarkers in the patient.
BIOMARKERS FOR ASSESSING PERIPHERAL NEUROPATHY RESPONSE TO TREATMENT WITH A PROTEASOME INHIBITOR